CJC-1295 is a synthetic peptide that mimics growth hormone releasing hormone (GGH). It binds to the receptors of the pituitary gland, stimulating the secretion of growth hormone, which, in turn, increases the level of insulin-like growth factor-1 (IGF-1).
Ipamorelin is a ghrelin—mimicking pentapeptide that acts on ghrelin receptors and stimulates the release of growth hormone without affecting cortisol or prolactin levels.
CJC-1295 is a long—acting GRH analog that binds to endogenous albumin, significantly increasing the half-life. CJC-1295 without DAC (often referred to as modified GRF 1-29 or CJC-1295 without DAC) retains 29 amino acids from natural GRH, but includes four substitutions to enhance stability and binding to receptors. This potentially mimics the more natural pulsating nature of growth hormone release.
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a selective growth hormone secretion stimulator (GHS) that mimics ghrelin, a hormone that stimulates the release of growth hormone from the pituitary gland. It is known to be highly effective and promotes the release of growth hormone (GH) without significantly affecting other hormones such as ACTH or cortisol, making it a unique candidate among growth hormone secretion stimulants.
A mixture of peptides can enhance GH release by acting on both GH and ghrelin receptors.
It is a mixture (10 mg) of each of CJC-1295 (without DAC) (5 mg) and Ipamorelin (5 mg).
The purity of peptides is more than 99%
Confirmed by certified laboratories. The analysis certificates are available before purchase.
GMR Production Standards
Manufactured in enterprises in accordance with good manufacturing practices. Complete documentation on tracking the origin of the product.
Execution of orders at the highest level
Sending orders the next day at checkout before 12:00 Moscow time. Free standard shipping across the country for orders starting from 15,000₽ (or equivalent).
Without fillers and additives
Only pure active connections. The composition is confirmed by experts for reliable in vitro studies.
CJC-1295 no DAC + Ipamorelin is a combined peptide complex that combines two different mechanisms of somatotropic axis stimulation. CJC-1295 no DAC is a short-acting GHRH analog without a DAC complex, and ipamorelin is a selective ghrelin receptor agonist GHSR-1a. Due to this combination, blend is usually considered in research as a combination of the GHRH pathway and the GHRP pathway, that is, as a model of more pronounced, but at the same time physiologically mediated stimulation of growth hormone secretion. For CJC-1295 no DAC, the FDA indicates a molecular weight of about 3367.97 g/mol, and for ipamorelin about 711.85 g/mol. December 4, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting
Growth Hormone stimulation
The main area of interest in CJC-1295 no DAC & Ipamorelin Blend is due to the fact that both components affect GH release through different receptor systems. CJC-1295 no DAC activates the GHRH receptor in the pituitary gland, and ipamorelin stimulates GHSR-1a as a selective growth hormone secretagogue. That is why such a combination is often described as more logical from a physiological point of view than using only one of the ways of stimulation. For ipamorelin itself, in the classic work of Raun et al. It showed high selectivity for GH without a marked increase in ACTH and cortisol, which made it one of the most interesting GHRP-like peptides. Ipamorelin, the first selective growth hormone secretagogue - PubMed
Pulse stimulation and lack of DAC
The key feature of this combination is that it uses the CJC-1295 no DAC, not the DAC version. This means that there is no albumin-binding complex and, consequently, a shorter duration of action compared to prolonged CJC-1295 DAC. Therefore, blend with no DAC is usually considered as an option for more brief and pulsed GH stimulation, whereas the contribution of ipamorelin complements this effect through the ghrelin pathway. From a scientific point of view, it is correct to describe such a bundle as a research combination for studying the short-term activation of the GH/IGF-1 axis, rather than as a long-acting GHRH analog. December 4, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting
Metabolic and anabolic studies
Since the GH/IGF-1 axis is involved in the regulation of protein metabolism, lipid metabolism, body composition, and regenerative processes, CJC-1295 no DAC & Ipamorelin Blend is also of interest in studies of metabolic adaptation, age-related decline in somatotropic function, and anabolic reactions. However, it is important to take into account that the clinical basis for the most ready-made combination as a single drug is limited, and most of the logic of its use is based on the pharmacology of individual components and their complementary mechanisms of action. This means that it is better to describe blend through its research concept, rather than through exaggerated claims of a proven result for the blend. Ipamorelin, the first selective growth hormone secretagogue - PubMed
The selectivity of ipamorelin
Ipamorelin gives a special value to this combination. Unlike a number of older GHRP, it has been studied as a more selective GH secretagogue with minimal effect on ACTH and cortisol. This property is often considered an advantage in research protocols where GH stimulation is important without unnecessary endocrine stress on other axes. Therefore, ipamorelin is usually described in blend as a component that enhances GH secretion through GHSR-1a with a relatively pure action profile. Ipamorelin, the first selective growth hormone secretagogue - PubMed
Links
1. U.S. Food and Drug Administration. December 4, 2024 Pharmacy Compounding Advisory Committee Meeting. Section on CJC-1295 free base and CJC-1295 DAC. December 4, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting
2. Teichman SL et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab, 2006. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults - PubMed
3. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 1998. Ipamorelin, the first selective growth hormone secretagogue - PubMed
4. U.S. Food and Drug Administration. October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee. Section on ipamorelin. October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee
5. Sigalos JT et al. The Safety and Efficacy of Growth Hormone Secretagogues. 2017. The Safety and Efficacy of Growth Hormone Secretagogues - PMC